Zoetis (NYSE:ZTS) Rating Reiterated by Piper Sandler

Piper Sandler restated their overweight rating on shares of Zoetis (NYSE:ZTS) in a report published on Tuesday morning, Benzinga reports. They currently have a $195.00 target price on the stock, down from their previous target price of $220.00.

A number of other research analysts have also weighed in on ZTS. Stifel Nicolaus decreased their target price on Zoetis from $215.00 to $195.00 and set a buy rating on the stock in a report on Tuesday, April 2nd. The Goldman Sachs Group upped their price objective on Zoetis from $190.00 to $226.00 and gave the company a buy rating in a report on Wednesday, January 17th. Barclays upped their price objective on Zoetis from $255.00 to $260.00 and gave the company an overweight rating in a report on Wednesday, February 14th. StockNews.com lowered Zoetis from a strong-buy rating to a buy rating in a report on Tuesday, February 20th. Finally, Jefferies Financial Group reaffirmed a buy rating and issued a $230.00 price objective on shares of Zoetis in a report on Tuesday, December 19th. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of Buy and a consensus target price of $221.75.

Zoetis Stock Down 4.3 %

NYSE:ZTS opened at $146.45 on Tuesday. The firm has a market capitalization of $66.98 billion, a price-to-earnings ratio of 28.89, a price-to-earnings-growth ratio of 2.32 and a beta of 0.85. Zoetis has a twelve month low of $145.80 and a twelve month high of $201.92. The stock’s 50 day moving average price is $175.48 and its two-hundred day moving average price is $180.02. The company has a quick ratio of 2.00, a current ratio of 3.36 and a debt-to-equity ratio of 1.32.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Tuesday, February 13th. The company reported $1.24 earnings per share for the quarter, missing the consensus estimate of $1.32 by ($0.08). The company had revenue of $2.21 billion for the quarter, compared to analyst estimates of $2.19 billion. Zoetis had a return on equity of 51.25% and a net margin of 27.43%. The firm’s revenue for the quarter was up 8.5% compared to the same quarter last year. During the same period last year, the firm earned $1.15 EPS. Equities research analysts expect that Zoetis will post 5.79 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 4th. Stockholders of record on Friday, April 19th will be given a dividend of $0.432 per share. The ex-dividend date is Thursday, April 18th. This represents a $1.73 dividend on an annualized basis and a dividend yield of 1.18%. Zoetis’s payout ratio is 34.12%.

Insider Activity

In other news, EVP Roxanne Lagano sold 923 shares of the company’s stock in a transaction on Thursday, April 18th. The stock was sold at an average price of $151.17, for a total transaction of $139,529.91. Following the completion of the sale, the executive vice president now directly owns 14,800 shares in the company, valued at approximately $2,237,316. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In the last three months, insiders sold 2,209 shares of company stock worth $371,293. 0.12% of the stock is currently owned by company insiders.

Institutional Trading of Zoetis

Several institutional investors and hedge funds have recently modified their holdings of the business. Hohimer Wealth Management LLC lifted its position in shares of Zoetis by 1.2% during the 4th quarter. Hohimer Wealth Management LLC now owns 4,386 shares of the company’s stock worth $866,000 after buying an additional 52 shares during the last quarter. Enterprise Financial Services Corp increased its holdings in Zoetis by 2.3% in the 1st quarter. Enterprise Financial Services Corp now owns 2,446 shares of the company’s stock worth $407,000 after purchasing an additional 55 shares in the last quarter. Forum Financial Management LP increased its holdings in Zoetis by 0.8% in the 4th quarter. Forum Financial Management LP now owns 7,386 shares of the company’s stock worth $1,458,000 after purchasing an additional 56 shares in the last quarter. Angeles Wealth Management LLC increased its holdings in Zoetis by 3.5% in the 4th quarter. Angeles Wealth Management LLC now owns 1,640 shares of the company’s stock worth $324,000 after purchasing an additional 56 shares in the last quarter. Finally, Prossimo Advisors LLC increased its holdings in Zoetis by 1.7% in the 4th quarter. Prossimo Advisors LLC now owns 3,498 shares of the company’s stock worth $690,000 after purchasing an additional 57 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.